news – page 12 – eisai china lnc.-nba直播小9直播

news – page 12 – eisai china lnc.-nba直播小9直播

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that a series of abstracts will be presented at the european society for medical oncology (esmo) virtual congress 2020 from september 19 to 21, 2020. the abstracts highlight updates regarding eisai’s in-house discovered lenvima® (lenvatinib mesylate, the orally available kinase inhibitor, “lenvatinib”), halaven® (eribulin mesylate, halichondrin class microtubule dynamics inhibitor, “eribulin”) and its liposomal formulation.

there will be two oral presentations regarding the combination therapy of lenvatinib and merck & co., inc., kenilworth, n.j., u.s.a. (known as msd outside of the united states and canada)’s anti-pd-1 antibody, keytruda® (pembrolizumab). both of these presentations have been selected as late-breaking abstracts. the interim results of the phase 2 study (leap-004) in advanced melanoma which had been treated with an anti-pd-1 or pd-l1 antibody (abstract no: lba44), as well as the interim results of the basket-type phase 2 study (leap-005) for 6 types (triple-negative breast cancer, ovarian cancer, gastric cancer, colorectal cancer, glioblastoma, and biliary tract cancer) of previously treated, advanced solid tumors (abstract no: lba41) will be presented.

there will also be an e-poster presentation (abstract no: 346p) on the expansion cohort of her2-negative breast cancer in a phase 1 study evaluating the eribulin liposomal formulation (e7389-lf) which aims to realize the efficient delivery to tumors.

in march 2018, eisai and merck & co., inc., kenilworth, n.j., u.s.a., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

this release discusses investigational compounds and investigational uses for fda-approved products. it is not intended to convey conclusions about efficacy and safety. there is no guarantee that any investigational compounds or investigational uses of fda-approved products will successfully complete clinical development or gain fda approval.

 

oral presentations*:

product / compound
abstract no.
abstract title and scheduled presentation date and time (cest)
lenvatinib
lba44
lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma that progressed on a pd-1 or pd-l1 inhibitor: initial results of leap-004
september 19 (sat), 16:32-16:44
lenvatinib
lba41
leap-005: phase 2 study of lenvatinib plus pembrolizumab in patients with previously treated advanced solid tumors
september 20 (sun), 14:25-14:37

*late breaking abstracts will be available on demand via esmo’s website on september 19.

 

e-poster presentations**:

product / compound
abstract no.
abstract title
lenvatinib
1313p
phase 3 leap-006 safety run-in (part 1): 1l pembrolizumab (pembro) chemotherapy (chemo) with lenvatinib (len) for metastatic nsclc
lenvatinib
973tip
leap-010: phase 3 study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (hnscc)
lenvatinib
1016tip
leap-012 trial in progress: pembrolizumab plus lenvatinib and transarterial chemoembolization (tace) in patients with intermediate-stage hepatocellular carcinoma (hcc) not amenable to curative treatment
lenvatinib
710p
phase 2 trial of lenvatinib (len) plus pembrolizumab (pembro) for disease progression after pd-1/pd-l1 immune checkpoint inhibitor (ici) in metastatic clear cell (mcc) renal cell carcinoma (rcc): results by independent imaging review and subgroup analyses
lenvatinib
719p
correlative serum biomarker analyses: lenvatinib (len) plus pembrolizumab (pembro) in a phase 1b/2 trial in advanced renal cell carcinoma (rcc)
lenvatinib
1668tip
a multicenter, open-label, randomized phase 2 study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with relapsed or refractory osteosarcoma (olie; itcc-082)
lenvatinib
1923p
assessment of the efficacy and safety of lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice in russia
e7389-lf
346p
phase 1 study of the liposomal formulation of eribulin (e7389-lf): results from the her2-negative breast cancer expansion
e7389-lf
583p
effect of infusion rate, premedication, and prophylactic peg-filgrastim treatment on the safety of the liposomal formulation of eribulin (e7389-lf): results from the expansion part of a phase 1 study
eribulin
316p
real-world treatment patterns and clinical effectiveness outcomes of eribulin in metastatic breast cancer patients in community oncology centers in the united states

**abstracts and e-posters will be available on demand via esmo’s website on september 14 and 17 respectively.

 

media inquiries:
public relations department,
eisai co., ltd.
81-(0)3-3817-5120

 

[notes to editors]

1. about the eisai and merck & co., inc., kenilworth, n.j., u.s.a. strategic collaboration
in march 2018, eisai and merck & co., inc., kenilworth, n.j., u.s.a., known as msd outside the united states and canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvima. under the agreement, the companies will jointly develop, manufacture and commercialize lenvima, both as monotherapy and in combination with merck & co., inc., kenilworth, n.j., u.s.a.’s anti-pd-1 therapy keytruda.

in addition to ongoing clinical studies evaluating the lenvima plus keytruda combination across several different tumor types, the companies have jointly initiated new clinical studies through the leap (lenvatinib and pembrolizumab) clinical program and are evaluating the combination in 13 different tumor types (endometrial carcinoma, hepatocellular carcinoma, melanoma, non-small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of the head and neck, urothelial cancer, biliary tract cancer, colorectal cancer, gastric cancer, glioblastoma, ovarian cancer and triple-negative breast cancer) across 19 clinical trials.

 

2. eisai’s focus on cancer
eisai focuses on the development of anticancer drugs, targeting the tumor microenvironment with experience and knowledge from halaven and lenvima and the driver gene mutation and aberrant splicing leveraging rna splicing platform as areas (ricchi) where real patient needs are still unmet, and where eisai can become a frontrunner in oncology area. eisai will discover innovative new drugs with new targets and mechanisms of action from these ricchi, and aims to contribute to curing cancers.

keytruda® is a registered trademark of merck sharp & dohme corp., a subsidiary of merck & co., inc., kenilworth, n.j., usa.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it will take over by transfer the manufacturing and marketing approval of parkinson’s disease treatment equfina® 50mg tablets (safinamide mesilate, “equfina”) in japan from meiji seika pharma co., ltd. (headquarters: tokyo, “meiji”), effective september 23, 2020.

in japan, meiji conducted clinical studies of equfina and obtained its manufacturing and marketing approval in september 2019. eisai has exclusively sold equfina in japan as a distributor. based on the license agreement signed between eisai and meiji, eisai will take over by transfer the manufacturing and marketing approval of equfina from meiji. eisai, as the manufacturer and distributor of equfina in japan, will continue to provide information on the proper usage of equfina.

equfina, developed by meiji in japan, is a once-daily oral treatment for parkinson’s disease. it is a selective and reversible monoamine oxidase b (mao-b) inhibitor that helps to maintain the density of endogenous dopamine and exogenous dopamine from levodopa-containing drugs in the brain (dopaminergic mechanism). in addition, equfina blocks voltage-dependent sodium ion channels and inhibits glutamate release (non-dopaminergic mechanism). in the clinical studies conducted in japan for parkinson’s disease patients under treatment with a drug containing levodopa, the extension of levodopa’s duration of effect (“on” time) of one hour or more and improvement of motor functions were shown. improvement effect on the wearing off phenomenon is expected.

following the completion of the transfer, eisai will continue to deliver equfina, a new option for parkinson’s disease treatment in japan to patients, thereby increasing the amount of time that they can freely engage in activities on their own initiative. eisai will further contribute to improving the qol of patients and enabling their families to create a vibrant daily life.

 

media inquiries:
public relations department,
eisai co., ltd.
81-(0)3-3817-5120

 

[notes to editors] 

1. about equfina (safinamide mesylate “safinamide”)

safinamide is a selective monoamine oxidase b (mao-b) inhibitor that reduces the degradation of excreted dopamine, helping to maintain the density of dopamine in the brain. additionally, safinamide blocks sodium ion channels and inhibits glutamate release, and as such has potential as a new parkinson’s disease treatment which possesses both dopaminergic and non-dopaminergic mechanisms.

safinamide was discovered and developed by newron pharmaceuticals s.p.a. (headquarters: milan, italy, “newron”). in 2011, newron entered into a licensing agreement with meiji, granting meiji exclusive rights to develop, manufacture and commercialize the drug in japan and asia. eisai has exclusive rights for marketing in japan, as well as for development and marketing in asia* based on a licensing agreement signed between eisai and meiji. safinamide mesilate is marketed under the name “xadago” in 15 countries in europe, the united states and australia, and under the name “onstryv” in canada.

* south korea, chinese taiwan, brunei, cambodia, laos, malaysia, the philippines, indonesia, thailand, vietnam, myanmar, singapore, hksa, and chinese macau

 

2.about parkinson’s disease

parkinson’s disease is a neurodegenerative disease that causes motor impairment such as shaking in the limbs, muscular rigidity and shuffling gait, as well as non-motor impairment such as sensation impairment with pain, insomnia, and autonomic failure. it is caused by degeneration of the dopamine nervous system, which leads to a shortage of dopamine, a neurotransmitter in the brain. according to an estimate by the japanese society of neurology, there are approximately 200,000 patients suffering from parkinson’s disease in japan.1 also, approximately 3 million patients suffer from parkinson’s disease in asia.2 the number of patients is increasing due to aging of the population.3 levodopa is widely used to treat parkinson’s disease by replenishing the brain’s supply of dopamine. however, as the disease progresses, the duration of effect of a drug containing levodopa (“on” time) decreases, and there are cases of parkinson’s disease symptoms returning before the next dose (“wearing-off” phenomenon). to prevent the “wearing-off” phenomenon, combination therapy with a drug that has a different mechanism of action to a drug containing levodopa is administered.

 

3. about meiji seika pharma

in order to protect and improve people’s health and lives, meiji seika pharma, as a “speciality and generic pharmaceuticals company”, runs its pharmaceutical business in two main fields: infectious disease and central nervous system disorders, as well as generic drugs. meiji seika pharma strives to respond to diversified medical needs and to contribute to the well-being of people worldwide.

for details, please visit its corporate website:

 

1 japanese society of neurology. treatment and management guideline 2018 for parkinson’s disease
2
 e ray dorsey et al. global, regional, and national burden of parkinson’s disease, 1990–2016: a systematic analysis for the global burden of disease study 2016 lancet neurol. 2018;17:939–53
3
 japan intractable diseases information center: 

the 7th “award ceremony for 2020 greater suzhou best employer and employer brand forum” was grandly held in the studio of suzhou radio and television general station recently. eisai china inc. stood out among thousands of participating enterprises with its good employer brand image, excellent performance of employer social responsibilities and excellent employee engagement, and has been awarded the “greater suzhou best employer” award for four consecutive years.

eisai china inc. wins “greater suzhou best employer” award for four consecutive years

the “greater suzhou best employer” project has been held for 7 consecutive years since 2013. the selection of the best employers in 2020 underwent four processes: expert review, employee survey, public voting and brand diagnosis, which lasted for three months. more than 200 entrepreneurs and human resources professionals in suzhou witnessed the birth of the “2020 greater suzhou best employer”. the “greater suzhou best employer” project is the most influential and appealing employer brand and selection activity in suzhou at present, and has become the annual employer brand display ceremony in suzhou. it has won this heavyweight trophy for four consecutive years, which represents the great recognition and affirmation of its years of devotion to its employer brand by the expert jury, society and employees.


photo of eisai china inc. at scene of award ceremony

 

since its entry into suzhou industrial park in 1996, eisai china inc. promotes tens of pharmaceutical brands in china, specializing in neurology, oncology and gastrointestinal areas, and has been rooted in suzhou industrial park for 24 years. it has always adhered to its business philosophy of hhc (human health care), provided chinese doctors with medical treatment support, and provided patients and their families with high-quality, environmentally friendly, safe and satisfactory products and services. it requires every employee to devote 1% of their working time to hhc activities every year, walk into communities together, approach patients, listen to the voices of patients and their families, and understand their sufferings, so as to better meet their needs.

it always regards the improvement of employees’ ability as one of its long-term strategies. in order to enhance the sense of belonging of employees and strengthen the corporate cohesiveness, the “honorary staff award” has been set up for employees who have served the company for 5, 10, 15 and 20 years respectively. the enhancement of employees’ ability and loyalty is the greatest reward and affirmation for an enterprise. it attaches importance to the personal value of each employee, and through the skill development system, it gives employees systematic training paths and clear development channels, and encourages everyone to solve problems with innovative thinking. meanwhile, it offers competitive remuneration and welfare, and provides employees with comprehensive care and protection. it is committed to providing a healthy and happy working environment for its employees and hopes to work with them to build itself into a respectable hhc company.

on september 1, 2020, the second hhc summit of eisai china holdings ltd. (hereinafter referred to as “eisai china”) was successfully held in shanghai. feng yanhui, senior vice president of eisai global, president of eisai china, and chairman of eisai china hhc committee, led the senior management team of eisai china and leaders of various departments to attend the summit.


feng yanhui delivered a speech 

feng yanhui said at the summit that hhc is based on well-being improvement for patients and their families to achieve business innovation; hhc is the mission, core philosophy and original intention of eisai china. all employees of eisai china should not forget the original intention, carry forward the hhc spirit, meet the unmet needs of patients and their families, and keep increasing their business innovation ability in their daily work.

the highlight of this summit was the combination of theory and practice. at the same time, 8 groups of patients were invited, and all participants were divided into 8 groups. a socialization process was undergone, that is, the staff members communicated with the patients, their families and people living together with them, discovered their needs, and shared and discussed hhc needs and put forward innovative ideas.


communication with patients (socialization)  

at the summit, awards were presented to those award-winning hhc projects and outstanding hhc fulfillers of eisai china in the 2019 fiscal year.


hhc committee members had a group photo taken with hhc award-winning representatives 

hhc stands for the initials of “human health care”, is the foundation of the global concept of eisai, and is consistent with the nursing concept of florence nightingale, the founder of modern nursing. the hhc logo is directly derived from the handwriting of florence nightingale.

the hhc philosophy is realized through the knowledge creation model -seci model, which is socialization, externalization, combination, and internalization respectively. the unmet needs of patients and their families are discovered through practice with the above model, and are met through actual work to realize business innovation.

on august 30, 2020, “the 37th china pharmaceutical industry information annual conference2020″ hosted by china pharmaceutical industry information center was held in zhuhai, guangdong province, and the conference released the list of the top 100 pharmaceutical enterprises in china in 2019, which attracted much attention from the industry. eisai china holdings ltd. (hereinafter referred to as “eisai china”) ranked the 71st, being on this list for five consecutive years. the ranking has risen from the 97th in 2015 to the 71st in 2019, manifesting the strong development of eisai china in recent years.


eisai china ranks 71st in list of top 100 pharmaceutical enterprises in china

with the theme of “innovation power”, this conference focused on the thoughts and explorations of new paths of innovation and development of chinese medicine in the post-covid19 period. the list of top 100 pharmaceutical enterprises in china reflects the economic operation of china’s pharmaceutical industry, in which enterprises are ranked according to the annual chinese pharmaceutical statistics report published by the ministry of industry and information technology. the entry threshold of the top 100 in 2019 was increased from 2.61 billion yuan in 2018 to 2.86 billion yuan. according to the statistics and analysis of china pharmaceutical industry information center, the top 100 enterprises in 2019 continued their consistent strong growth momentum, with their main business income reaching 929.64 billion yuan, up by 10.7%. driven by the leading role of the top 100 enterprises, the pharmaceutical industry enterprises have maintained strong revenue capacity and sufficient development momentum. the list of top 100 pharmaceutical enterprises in china can stimulate the innovative impetus of more enterprises, drive more enterprises to transform and upgrade, and promote the high-quality development of china’s pharmaceutical industry.


ms. rao ying from access management division of eisai china received the award on behalf of the company

eisai china has been developing smoothly since it entered the chinese market in the early 1990s. it has set up shenyang eisai pharmaceutical co., ltd and eisai (suzhou) pharmaceutical co., ltd. since 1991, and was officially renamed eisai china inc. in 2002. with the business development in china, eisai (suzhou) trade co., ltd. was established in 2010, eisai holdings ltd. was established in 2014, and eisai (liaoning) pharmaceutical co., ltd. was officially established in 2015 through full acquisition of local generic pharmaceutical enterprises. so far, a development mode has been formed, consisting of eisai china holdings ltd. for capital control and management, while eisai china inc., eisai (liaoning) pharmaceutical co., ltd. and eisai (suzhou) trading co., ltd. for business support. in november 2018, the new factory in suzhou of eisai china was opened for business. it is one of the main factories of the group, and the products it produces will not only meet the demand of the chinese market, but also be supplied to 23 countries and regions such as east asia, southeast asia, middle east, central and south america and europe. eisai china’s sales have been among the highest among the japanese-funded pharmaceutical companies in china for more than 10 consecutive years.

eisai china will always uphold its business philosophy of hhc (human health care) and provide patients and their families with high-quality, environmentally friendly, safe and satisfactory products and services. hopefully eisai china can work with all its employees to build itself into a respectable hhc company. 

sahne medical spray is the first otc drug spray-type lotion containing heparinoid

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has launched sahne® medical spray and sahne® medical cream (both are category-2 otc drugs, “sahne medical”) on august 25, 2020 at pharmacies and drugstores throughout japan, as a new product of the sahne brand lineup which has been a favored hand care for generations.

 

eisai conducted a survey of 1,000 women in their 40s to 50s in april 2020. as a result, it was found that approximately 70% of the subjects felt that the dryness of their skin and/or the dry skin expanse had increased compared to its condition five years ago. additionally, a number of comments regarding the discomfort of dryness from people with dry skin were received as follows: “the dryness has spread to my thighs, shins, sides, and back.”, “i’m distracted just by my underwear rubbing against my skin.”, and “my dry skin flakes stick inside my clothes whenever i get undressed, which makes me uncomfortable.” it is considered that the skin condition of women after their late 30s requires more reliable moisturizing effects of pharmaceuticals, since the amounts of sebum, natural moisturizing factors, and intercellular lipids in the stratum corneum necessary for water retention of the skin decrease.

“sahne medical” is a category-2 otc drug containing the active ingredient “heparinoid”, which exerts a high moisturizing effect against dry skin (xeroderma) that worsens with age. heparinoid penetrates into the stratum corneum, increases natural moisturizing factors, and restores the structure of intercellular lipids in the stratum corneum to moisturize dry skin.

there are two types of product lines, spray and cream, which can be selected depending on the part of the body where the product is applied and/or the principles of tpo (time, place and occasion). “sahne medical spray” is the first otc drug spray-type lotion containing heparinoid. this product is handy for the consumer to use on the back, side and back of thigh, where it is difficult to apply the medicine by themselves, as it features a container that can be sprayed upside down and a fine mist-like lotion. in addition, the tube-type “sahne medical cream” is recommended for relieving unbearable discomfort of dryness upon going out, as it is convenient to carry.

the sahne brand has continued to be a gentle companion to the daily lives of many people for 66 years since its launch. with the new launch of sahne medical, a pharmaceutical product, eisai is now able to provide a remedy for skin problems that it had not been able to contribute to before. eisai will further respond to the wishes of consumers who want to be relieved of the discomfort of dry skin, with the moisturizing effect of pharmaceutical care products and the gentle nature of sahne products.

 

media inquiries:
public relations department,
eisai co., ltd.
81-(0)3-3817-5120

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that a total of 10 presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: dayvigotm civ) will be given at the 34th annual meeting of the associated professional sleep societies (sleep 2020), to be held virtually from august 27 to 30, 2020.

the main presentations from eisai at this conference include presentations relating to the sunrise 2 phase iii clinical trial conducted globally, including sites in japan: long-term efficacy and safety results of lemborexant in elderly adults with insomnia (oral presentation, presentation number o-01, 474), responder profiles on treatment with lemborexant (poster number 479), efficacy and safety results of lemborexant in perimenopausal female subjects with insomnia (poster number 480), and others.

lemborexant is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (ox1r and ox2r). lemborexant acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythms. lemborexant was approved in the u.s. for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, and was approved in japan for the treatment of insomnia. the clinical development of lemborexant in patients with irregular sleep wake rhythm disorder (iswrd) associated with mild-to-moderate alzheimer’s dementia is ongoing.

insomnia is characterized by difficulty falling asleep, staying asleep, or both, despite an adequate opportunity to sleep, that can lead to daytime consequences, such as fatigue, difficulty concentrating and irritability.1,2 insomnia is one of the most common sleep-wake disorders. approximately 30% of adults worldwide have symptoms of insomnia.3,4 in particular, older adults tend to have a higher prevalence rate with many experiencing insomnia symptoms for months to years. as a result, insomnia causes various social losses, such as long absences and reduced productivity.

eisai positions neurology as a key therapeutic area, and it will continue to create innovation in the development of new drugs based on cutting-edge neurology research as it seeks to contribute further to improving the benefits of patients and their families in diseases with high unmet needs, such as insomnia.

 

■ virtual oral presentation:

presentation number title・planned date and time (central daylight time)
oral o-01
474
long-term efficacy and safety of lemborexant in elderly adults with insomnia disorder: results from sunrise-2
august 28 (fri) 11:52 am – 12:03 pm

    

■ virtual poster presentation:

presentation number title
poster 473 effectiveness and safety of lemborexant in subjects previously treated with placebo for 6 months in sunrise-2
poster 477 characteristics of insomnia subjects screened for transitioning from zolpidem tartrate to lemborexant in a multicenter pilot study
poster 478 a multicenter pilot study to evaluate next-dose transition from zolpidem to lemborexant for the treatment of insomnia
poster 479 sleep onset and sleep maintenance responder profiles over 12 months of treatment with lemborexant: results from sunrise-2
poster 480 efficacy and safety of lemborexant in female subjects of perimenopausal age with insomnia disorder
poster 481 impact of lemborexant on fatigue severity in subjects with clinically significant levels of fatigue at baseline
poster 484 how much improvement in subject-reported sleep onset latency is needed for patients to report a positive impact of their insomnia medication?
poster 485 experience and attitudes about prescription insomnia medications: results from an online survey of individuals with sleeping difficulties and insomnia
poster 486 impact of intrinsic factors on efficacy of lemborexant: subgroup analyses of sunrise-2

 

media inquiries:
public relations department,
eisai co., ltd.
81-(0)3-3817-5120

 

[notes to editors]

1. about lemborexant

lemborexant is eisai’s in-house discovered and developed small molecule that binds to orexin receptors, ox1r and ox2r, and acts as a competitive antagonist (ic50 values of 6.1 nm and 2.6 nm, respectively). the mechanism of action of lemborexant in the treatment of insomnia is presumed to be through antagonism of orexin receptors. the orexin neuropeptide signaling system plays a role in wakefulness. blocking the binding of wake-promoting neuropeptides orexin to receptors ox1r and ox2r is thought to suppress wake drive (ki values of 8.1 nm and 0.48 nm, respectively). higher affinity and faster on/off receptor kinetics of lemborexant to orexin receptor 2, which also suppresses non-rem sleep, indicates its potential to facilitate non-sedative onset and maintenance of sleep. in june 2020, dayvigo was launched in the u.s. for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance; and in july 2020, dayvigo was launched in japan for the treatment of insomnia. in addition, eisai has submitted new drug applications seeking approval of dayvigo in canada, australia and hksa. in addition, a phase ii clinical study of lemborexant in patients with irregular sleep wake rhythm disorder (iswrd) associated with mild-to-moderate alzheimer’s dementia is underway.

 

2. about sunrise 2study 303

sunrise 2 is a 12-month multicenter, global (japan, north america, south america, europe, asia, and oceania), randomized, placebo-controlled, double-blind, parallel group phase iii study of 949 male or female adult participants (18 to 88 years of age) with insomnia disorder. sunrise 2 included a pre-randomization phase of up to 35 days (including a two-week placebo run-in period) and a randomization phase comprised of a six-month placebo-controlled treatment period, a six-month period of only active treatment, and a two-week period without treatment prior to the end-of-study-visit. lemborexant 5 mg, 10 mg or matching placebo was taken orally in tablet form at home each night immediately before the patient intended to try to sleep for the first six months of study. patients who received placebo during the first six-month period were administered lemborexant 5 mg or 10 mg for the second six-month period. patients who received active treatment during the first period continued on the treatment to which they were originally randomized.

the primary outcome measure was mean change from baseline in subjective sleep onset latency after six months of placebo-controlled treatment. key secondary outcome measures were mean change from baseline in subjective sleep efficiency and subjective wake after sleep onset after six months of placebo-controlled treatment.

from the results, the primary endpoint and all secondary endpoints for efficacy were achieved for lemborexant arms, and statistically significant improvements in sleep onset and sleep maintenance were confirmed for lemborexant  arms compared to placebo during the six-month treatment period. the common adverse events in the lemborexant arms were somnolence, nasopharyngitis, headache and influenza.

 

1 institute of medicine. sleep disorders and sleep deprivation: an unmet public health problem. washington, dc: national academies press. 2006.
2 ohayon mm, et al. epidemiology of insomnia: what we know and what we still need to learn. sleep med rev. 2002;6(2):97-111.
3 ferrie je, et al. sleep epidemiology – a rapidly growing field. int j epidemiol. 2011;40(6):1431–1437.
4 roth t. insomnia: definition, prevalence, etiology and consequences. j clin sleep med. 2007;3(5 suppl):s7–s10.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and msd k.k. (headquarters: tokyo, president: jannie oothuizen, “msd”), a subsidiary of merck & co., inc., kenilworth, n.j., u.s.a., announced today that eisai has submitted an application in japan for the additional indication of treatment of unresectable thymic carcinoma for multiple receptor tyrosine kinase inhibitor lenvima ® (generic name: lenvatinib mesylate). in june 2020, lenvima received orphan drug designation in japan for unresectable thymic carcinoma.

this application is based on the results of an open-label, single-arm, multicenter, investigator-initiated clinical phase ii study (ncch1508) conducted in japan, evaluating lenvima as a single agent in 42 patients with thymic carcinoma previously treated with at least one platinum-based regimen.

the primary endpoint of this study, objective response rate (orr, assessed by independent imaging review) was 38.1% (90% confident interval (ci): 25.6-52.0). this study met its endpoint as the lower value of the ci exceeded the pre-specified statistical criteria, a threshold orr of 10%. the most common three treatment-related adverse events were hypertension (88.1%), proteinuria (71.4%), and palmar-plantar erythrodysesthesia syndrome (69.0%), which is consistent with the safety profile observed in the previously approved indications.

thymic carcinoma is an extremely rare disease with low prevelance. it is estimated that there are only 140 to 200 patients in japan. for unresectable thymic carcinoma, platinum-based first-line therapy is recommended. however, since the standard treatment has not yet been established for second-line or later therapy, it remains a disease with a poor prognosis, thus the development of new therapeutic agents is desired.

eisai and msd have been collaborating through the provision of information on lenvima in japan since october 2018, and will work together to expedite the maximization of lenvima’s contribution to patients with cancer.

 

media inquiries
eisai co., ltd.
public relations department
tel: 81-(0)3-3817-5120

msd k.k.
communication department
tel: 81-(0)3-6272-1001


1. about lenvima® (generic name: lenvatinib mesylate)
lenvima, discovered and developed by eisai, is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (vegf) receptors vegfr1 (flt1), vegfr2 (kdr), and vegfr3 (flt4). lenvima inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (fgf) receptors fgfr1-4, the platelet derived growth factor receptor alpha (pdgfrα), kit, and ret. in syngeneic mouse tumor models, lenvima decreased tumor-associated macrophages, increased activated cytotoxic t cells. currently, lenvima has been approved for monotherapy as a treatment for thyroid cancer in over 65 countries including japan, the united states, in europe and in asia, and for unresectable hepatocellular carcinoma in over 65 countries including japan, the united states, in europe, china and in asia. additionally, it is also approved in combination with everolimus as a treatment for renal cell carcinoma following prior antiangiogenic therapy in over 55 countries, including the united states, in europe (where it was launched under the brand name kisplyx® for renal cell carcinoma) and in asia. in addition, it is approved in combination with keytruda® (generic name: pembrolizumab) as a treatment for advanced endometrial cancer that is not microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation in countries including the united states, australia, and canada. continued approval for this indication is contingent upon verification and description of clinical benefit in the confirmatory trials.

2. about ncch1508 (remora study)*
this study is an open-label, single-group, multicenter, investigator initiated clinical phase ii study (8 centers nationwide including the national cancer center hospital). forty-two patients with thymic carcinoma were enrolled who had progressed after at least one prior platinum-based therapy. the primary endpoint is objective response rate (orr) by independent image review using recist1.1, and secondary efficacy endpoints include progression free survival (pfs), disease control rate (dcr), and overall survival (os). lenvatinib was administered at a starting dose of 24 mg once daily, and the dose was appropriately reduced according to the patient’s condition until the disease progressed or unacceptable toxicity was observed.

for efficacy analysis, orr was 38.1% (90% confidence interval (ci): 25.6-52.0) and the best overall response was 38.1% for partial response, 57.1% for stable disease, and 4.8% for disease progression. pfs (median) was 9.3 months (95% ci: 7.7-13.9), dcr was 95.2% (95% ci: 83.8-99.4), and the median os was not reached (95% ci: 16.1-nr (not reached)). the major treatment-related adverse events** (more than 30%) were hypertension (88.1%), proteinuria (71.4%), palmar-plantar erythrodysesthesia syndrome (69.0%), hypothyroidism (64.3%), diarrhea (57.1%), thrombocytopenia (54.8%), decreased appetite (42.9%), weight loss (40.5%), dysphonia (40.5%), increased aspartate aminotransferase (33.3%), malaise (33.3%), and stomatitis (33.3%).

*   jun sato, miyako satouchi, shoichi itoh, yusuke okuma, seiji niho, hidenori mizugaki, haruyasu murakami, yasuhito fujisaka, toshiyuki kozuki, kenichi nakamura, yukari nagasaka, mamiko kawasaki, tomoaki yamada, ryunosuke machida, aya kuchiba, yuichiro ohe, noboru yamamoto; lenvatinib in patients with advanced or metastatic thymic carcinoma (remora): a multicentre, phase 2 trial. the lancet oncology, 2020, vol.21, no. 6, p843-850
** the adverse event data used for the application has beed updated from the data in the paper.

3. about the eisai and merck & co., inc., kenilworth, n.j., u.s.a. strategic collaboration
in march 2018, eisai and merck & co., inc., kenilworth, n.j., u.s.a., known as msd outside the united states and canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvima. under the agreement, the companies will jointly develop, manufacture and commercialize lenvima, both as a monotherapy and in combination with merck & co., inc., kenilworth, n.j., u.s.a.’s anti-pd-1 therapy keytruda® (generic name: pembrolizumab).

in addition to ongoing clinical studies evaluating the lenvima plus keytruda combination across several different tumor types, the companies have jointly initiated new clinical studies through the leap (lenvatinib and pembrolizumab) clinical program and are evaluating the combination in 13 different tumor types (endometrial carcinoma, hepatocellular carcinoma, melanoma, non-small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of the head and neck, urothelial cancer, biliary tract cancer, colorectal cancer, gastric cancer, glioblastoma, ovarian cancer and triple-negative breast cancer) across 19 clinical trials.

4. about eisai co., ltd.
eisai is a leading global research and development-based pharmaceutical company headquartered in japan, with approximately 10,000 employees worldwide. eisai defines our corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which we call our human health care(hhc) philosophy. we strive to realize our hhc philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including oncology and neurology. in the spirit of hhc, eisai takes that commitment even further by applying our scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address society’s toughest unmet needs, including neglected tropical diseases and the sustainable development goals.

for more information about eisai, please visit  (for global), (for u.s.) or  (for europe, middle east, africa), and connect with us on twitter ( and ) and  (for u.s.).

5. about msd
for more than 125 years, msd has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. msd is a trade name of merck & co., inc., with headquarters in kenilworth, n.j., u.s.a. we demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. today, msd continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as hiv and ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. for more information, visit  and connect with us on , and .

eisai dementia platform easiit commences

 

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and dena co., ltd.’s subsidiary desc healthcare co., ltd. (headquarters: tokyo, ceo: sho segawa, cmo: kuniaki miyake, “dena”) announced that they have begun provision of the brain performance application “easiit” (non-medical device, referred to below as “easiit app”), for preparation against dementia, on july 28, 2020. this provision is based on a business alliance agreement aiming for support and creation of new solutions in the dementia area as well as co-development of the easiit app as a base element of the digital platform for dementia that eisai is currently constructing. with the beginning of provision of the easiit app, the eisai dementia platform easiit has commenced.

eisai possesses over 35 years of experience in medicine creation and business activity in the dementia field, and dena has demonstrated performance in providing healthcare services and altering consumer behavior while applying know-how from its gaming and sports industry experiences with the theme of “staying healthy with fun”. both companies aim to contribute towards better health practices by all people through such approaches as visualizing brain and body health data, supporting brain performance maintenance, and providing useful lifestyle information. both companies will continue their efforts in partnership for creating the digital platform, including the expansion of functions of the easiit app.

 

background on the co-development and provision of the easiit app

in its medium-term business plan, eway2025, eisai is aiming to become a “medico societal innovator”, a company that changes society through creating medicines and providing various innovative solutions that change society. particularly in the dementia field, eisai is collaborating with partners such as medical organizations, diagnostic development companies, research organizations, and bio-ventures in addition to private insurance agencies, fitness clubs, automobile makers, retailers, and care facilities to realize construction of a “dementia ecosystem” for delivering new benefits. the base of this ecosystem will be the dementia platform easiit. through this platform, eisai aims to collect information from participants, combine this information with eisai’s independent data set comprising elements such as know-how, experience, and clinical data, and perform analysis in compliance with relevant regulations in order to deliver new benefits to participants in the form of various healthcare predictions and advice.

dena’s healthcare business aims for the extension of “healthy life expectancy” by realizing the conversion of “sick care” through treatment after becoming sick to “healthcare” through preventing sickness from occurring. dena provides various internet based healthcare services that apply its unique know-how for making enjoyable user experiences and extending use as cultivated through its activities in the gaming and sports fields.

in recent years, various research has demonstrated the possibility that decline in brain health may be mitigated through readjustments to lifestyle such as regular exercise, a well-balanced diet, and social interaction. on the other hand, according to a survey conducted by eisai, the number of people who understand the correct preventive measures or perform cognitive function checks regularly are few, which indicates disparities (“chasms”).

the easitt app, which aims to contribute to the promotion of healthy habits by making brain and body health visible, is core to eisai’s digital platform business directed at eliminating these chasms. both companies combined their respective strengths to co-develop this app, and have now begun provision of the first version.

 

the brain performance app “easiit app”

in the easiit app, a menu of individualized recommendations based on users’ footsteps, diet, sleep, and weight records (lifelog) is updated on a weekly basis and displayed. individualized scoring is conducted based on actions and habits which are good for brain performance. the easiit app confirms score changes and breakdown, and encourages formation of good habits for brain performance moving forward. for diet record in particular, easy diet management is made possible as the easiit app evaluates users’ meals via photo upload for calorie intake and eleven essential nutrients, and displays this information in relation to an age-based standard for calorie and nutrient intake. additionally, with every use of the app one can collect easiit miles, which can be exchanged for prizes such as gift cards. through connection to wearables and subsequent functions such as sleep time tracking, the easiit app can encourage the creation of good habits for brain performance.

all of the functions within the easiit app are designed, developed, and operated on a framework for protection of individual information.

planned functions moving forward

in the end of september of this year, eisai plans to equip the easiit app with a linkage to the brain performance self-check tool “nouknow” (non-medical device), which eisai is currently selling to legal entities. in the future, the addition of a new function is planned for use in families in which members are living separately from each other.

additionally, eisai is investigating future equipment of the easiit app with a function allowing for connection to medical data (as a non-medical device) on top of daily lifestyle data.

 

commentary from persons in charge of operations in both companies

eisai vice president, president of dementia total inclusive ecosystem business unit and chief digital officer keisuke naito said, “i believe that recording the health state of one’s brain and body alike and making those records visible is critical to the realization of one’s well-being in one’s own way. this app, which we have co-developed with dena, enables one to easily record one’s footsteps, sleep time, diet, nutrient deficiencies, and other elements. through the expansion and wide adoption of the easiit app, we will work steadfastly in this first step towards the realization of a society in which anyone may measure their own brain performance easily, make lifestyle improvements for the future, and receive early stage medical examination.”

dena vice president, head of healthcare business division and president of desc healthcare co., ltd. sho segawa said, “i encountered eisai at a time when i was watching my parents care for my grandfather, who had developed dementia, and thinking to myself, ‘is there not something i can do as a player of the healthcare industry?’. with the combination of eisai’s experience in the dementia field and dena’s services, we will concentrate our expertise for encouraging and sustaining enjoyable healthy lifestyles in the easiit app, making an effort to accelerate the creation of solutions for dementia.”

 

[notes to editors]

1. about brain performance (brain health) and issues surrounding it

in recent years, various research has demonstrated the possibility that decline in brain performance (brain health) may be mitigated through major readjustments to lifestyle such as regular exercise, a well-balanced diet, and social interaction. on the other hand, according to survey* conducted by eisai on men and women in japan between forty and seventy-nine years of age, it was revealed that 55.7% of participants understood the meaning and contents behind early assessment and prevention, 19.7% of participants were taking correct preventive actions in diet, exercise, sleep, etc. on a regular basis, and no more than 2.1% of participants were habitually performing self-assessments of cognitive function. these statistics represent disparities (“chasms”) which must be overcome in order to promote disease understanding and the incorporation of cognitive function checks into daily lifestyle.

*independent online survey conducted in december 2019 by eisai in japan on participants in their 40’s, 50’s, 60’s, and above 70, with 200 male and 200 female participants per age bracket (total: 1,600).

 

2. summary of easiit app details

availability: ios version available july 28, 2020 (tuesday), android version planned availability for end of august 2020.

cost: free of charge; the high function edition with various additional contents and continuous individual data visualization is to be launched for a charge in the winter of 2020.

 

supervising editor: dr. atsushi iwata, director, department of neurology, tokyo metropolitan geriatric hospital and institute of gerontology

easiit website: 

 

  • presents weekly menu customized for the user, including suggestions for exercise, diet, sleep, etc.
  • presents footstep count, diet record, sleep time, and body weight in graph form for user confirmation
  • evaluates users’ meal photos for amount of calories and eleven essential nutrients and displays this information in relation to an age-based standard for intake
  • awards easiit miles with every use, which can be collected and exchanged for gift cards, etc.
  • connects with the fitbit wearable device to automate footstep count, sleep time, and body weight measurement
  • conducts individual scoring [easiit score] based on records of actions and habits which are good for brain performance in correspondence with the menu. the easiit score provides a positive motivation for the user to practice a lifestyle that is good for brain performance.

3. about the dementia ecosystem business

leveraging experience gained from the development and marketing of aricept®, a treatment for alzheimer’s disease and dementia with lewy bodies, eisai aims to establish the “dementia platform easiit” for analyzing participants’ health and lifestyle information and subsequently providing advice on brain health. in the future, eisai is planning to evolve this platform to a digital platform that spans areas of daily life and medicine.

with the digital platform as a base, eisai aims to construct a “dementia ecosystem” for delivering new benefits by collaborating with partners such as medical organizations, diagnostic development companies, research organizations, and bio-ventures in addition to private insurance agencies, finance, fitness clubs, automobile makers, retailers, and care facilities.

 

4. about eisai co., ltd.

eisai co., ltd. is a leading global pharmaceutical company headquartered in japan. eisai’s corporate philosophy is based on the human health care (hhc) concept, which is to give first thought to patients and their families, and to increase the benefits that health care provides to them. with a global network of r&d facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of neurology and oncology. for more information about eisai co., ltd., please visit .

 

5. about dena’s healthcare initiatives

with its healthcare business mission of “staying healthy with fun”, dena provides healthcare services such as its gene screening service “mycode” and its healthcare engagement app “kencom” aimed at healthcare insurance agencies and municipalities, applying engagement science as cultivated through its gaming and sports businesses. dena was selected in 2019 and 2020 consecutively for the “health and productivity branding”, a designation that is granted by japan’s ministry of economy, trade, and industry in collaboration with the tokyo stock exchange for companies that are evaluated to think and act strategically with an operational perspective for the health of their employees.

 

6. about dena co., ltd.

dena co., ltd.’s corporate mission is to “delight and impact the world”. applying its strengths in internet and ai, dena aims to create various solutions for various social issues in fields ranging from entertainment, including gaming and social concerts, to an expanding sports presence, including sponsorship of the yokohama bay stars baseball team, as well as in the healthcare and automotive industries. for more information about dena co., ltd., please visit .

 

media inquiries
eisai co., ltd.
public relations department
tel : 81-(0)3-3817-5120

dena co., ltd.
pr group
e-mail: pr@dena.jp

preventing medical infrastructure collapse by a monitoring system linked to line

allm inc. (shibuya-ku, tokyo, president: teppei sakano, hereafter allm), tokyo medical and dental university (bunkyo-ku, tokyo, president: yujiro tanaka) and eisai co., ltd. (headquarters: bunkyo-ku, tokyo, ceo: haruo naito, hereafter eisai) announced that their jointly submitted study and development project has been selected by the japan agency for medical research and development (amed) for its publicly advertised 2020 “field of support for experimental study on medical devices and systems that contribute to measures against viruses and other infectious diseases” as part of its “technology development project for measures against viruses and other infectious diseases “, and that allm has entered into an industry-academia-government joint research agreement with tokyo medical and dental university and eisai respectively.

the selected study and development project is as follows:

study of the monitoring system for covid-19 patient on the home/hotel recuperation.

representative organization: allm inc.

duration of study and development: from grant delivery decision date during 2020 until march 31, 2021 (1 year).

(reference) amed website (japanese only)

 

■summary of the experimental study

since april 2020, allm has been operating a medical treatment administration system linking the communication application “line” and the medical information collaboration system “team”, developed and operated by allm, for use in treatment of patients with mild cases of the novel coronavirus infection at home or in accommodations in kanagawa prefecture. on the other hand, while vital signs such as body temperature in addition to blood pressure, respiratory rate, and spo2 are indispensable for the physical management of medical care recipients, measurement equipment supplies were not sufficient. accommodation care facilities were insufficient such that among patients testing positive, those with mild symptoms or without symptoms had to share accommodations. provision for patients receiving treatment at home was even more difficult. with predicted increases in patients yet to come, establishment of a system to allow for arrangement of secure medical treatment at home became an urgent task. therefore this study will apply widely used smartphone and sns technologies and add a function that allows for remote acquisition of various data that contribute to medical decision making to an existing communication system, without requiring special knowledge or equipment from users. demonstrations are planned in kanagawa prefecture and tokyo metropolis.

this study will first implement a non-contact body monitoring function in the lifesaving and health support application “mysos” developed by allm. this function is equipped with ai to measure vital signs including spo2, respiratory rate, and blood pressure using a smartphone camera.

the vital information obtained by this function is applied to optimize the content of a medical inquiry, sent to the patient through line chat, according to the patient’s condition. in addition, the following three points will be verified by combining an olfactory test (classified as miscellaneous goods) provided by eisai with other commercially available antibody tests and antigen tests, under the supervision of tokyo medical and dental university:

    1. designation of remote assessment criteria for patient consultation to eliminate patient anxiety and prevent inundation of medical institutions
    2. construction of an alert system that predicts serious deterioration, in order to prevent sudden changes and serious deterioration of patients receiving medical treatment at home.
    3. designation of criteria for determining when medical treatment may be ended and the patient may return to society

this study aims to make a great contribution to solving problems in the medical field by enhancing communication with medical institutions through ai and ict in situations where the work of medical institutions and public health centers is saturated and patients’ anxiety is amplified due to the rapid spread of infection.
■ about amed’s “technology development project for measures against viruses and other infectious diseases”

in response to the global spread of the novel coronavirus infection (covid-19), expectations are high for the development of simple, rapid and decentralized virus tests, systems for preventing the spread of infection, and development of therapeutic devices for critically ill patients. in light of these expectations, we will support research and development that will lead to the resolution of problems caused by infectious diseases, as well as the development and verification of equipment and systems that meet the needs of the field for measures against the novel coronavirus infection.

■ about mysos

mysos is an application developed and provided by allm inc. that records the health and medical records of patients and their families, and supports a smooth response in the event of an emergency. since mysos allows for medical examination results and medical images such as mri and ct to be checked via smartphone, this app can also be used as a phr (personal health record) and may thus play a role in daily health management.

■ about team

team is a solution developed and provided by allm inc. that seamlessly connects medical and nursing care services and supports the promotion of a regional comprehensive care system. it enables information sharing and collaboration among professions based on operation records stored in the applications “kaigo” and “kango” for the nursing care business and the nursing business, respectively.

■ about allm

allm inc. has cited “shaping healthcare” as its corporate message, as a company that “supports all medical care (all medical)” through providing mobile ict solutions in the medical and welfare fields. in addition, in the medical ict business, including the application “join” for communication among medical personnel, we are actively engaged in global expansion and providing solutions to 19 countries as a medical ict company originating in japan.

  • company name: allm inc
  • head office: yushin bldg. shinkan 2f, 3-27-11 shibuya, shibuya-ku, tokyo, zip code: 150-0002 japan
  • representative director/ceo: teppei sakano
  • founded: april 18, 2001
  • capital: 1,541,650,000 yen
  • website: 

※mysos and team are trademarks or registered trademarks of allm, inc.

 

■ about tokyo medical and dental university

tokyo medical and dental university was founded in october 12, 1928 as the administration, in the yushima/shohei hill area of tokyo famed as a place for education and learning. through the blending of medicine and dental medicine, tokyo medical and dental university was created as the only comprehensive medical institution in japan under the slogan “carpenter of knowledge and healing”, practicing innovative medical care in japan and contributing to the health of individuals and the welfare of society. for more information, please visit the university website:

 

■ about eisai

eisai co., ltd. is a leading global research and development-based pharmaceutical company headquartered in japan. we define our corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which we call our human health care (hhc) philosophy. with approximately 10,000 employees working across our global network of r&d facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of neurology and oncology. as a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

for more information about eisai co., ltd., please visit .

 

contact information:
allm inc. team
platform department pr
tel: 03-6418-3012
email: press@allm.jp

national university corporation tokyo medical and dental university
tel: 03-5803-5833 fax: 03-5803-0272
email: kouhou.adm@tmd.ac.jp

eisai co., ltd.
pr department
tel:03-3817-5120

网站地图